Richard Still has a strong background in finance, operations and corporate startups. He has most recently served as CFO of a 100 million dollar privately held company. His previous positions included COO of a multi-location environmental company, financial analyst for an investment banking firm and plant manager for a manufacturing company.

Richard was also the founder and CEO of three different companies. Richard has a Bachelor of Science degree in mechanical engineering from Duke University and MBA from Columbia University School of Business.

Dr. David E. Martin is a highly accomplished translational scientist with more than 30 years of hands-on drug development experience across the spectrum of drug discovery, preclinical development, Phase I-IV clinical development, and regulatory affairs. He has been responsible for managing more than 30 discovery/early phase clinical programs in a variety of therapeutic areas: cardiovascular, inflammation, respiratory, and HIV. Dr. Martin has published more than 142 peer-reviewed, scientific publications and has 17 granted/provisional patents. He received his PharmD from the University of Southern California (USC) and completed his Residency in Clinical Pharmacy at the USC School of Pharmacy followed by a Fellowship in Drug Development at The University of North Carolina, Chapel Hill and Glaxo, Inc.

Dr. Sancilio is a serial entrepreneur in the healthcare field and is currently a principle of Clearway Global, Inc., a pharmaceutical development advisory service. He is also president and serves on the board of directors of Alpha Cognition, Inc., a Canadian biotechnology company that is developing neurological products to treat Alzheimer’s and Lou Gehrig’s diseases.

Dr. Sancilio received his Master of Science and Doctorate degrees from Rutgers, The State University of New Jersey. For over four decades, he has contributed to the development of over 1,000 drug products marketed worldwide, holds numerous patents, and has written dozens of scientific publications. Fred served as a research professor and managing director of Translational Development & Commercialization at Florida Atlantic University and was an adjunct professor of chemistry at the University of North Carolina.

Billy Meadow is a serial technology entrepreneur and has thrived for decades in commercializing and funding companies like TrippBio, based on the ideas of professors and research scientists. His latest company, SpinUp Campus, focuses on matching forward-thinking university scientists with public angel investors to bring new drug treatments and medical innovations to market. He excels at business strategy and is seasoned in the art and science of start-up company success. Billy has a Bachelor of Science degree in business from Florida State University.